Wedbush reissued their outperform rating on shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) in a report published on Tuesday. The brokerage currently has a $26.00 price target on the stock. Wedbush also issued estimates for Corvus Pharmaceuticals’ Q2 2017 earnings at ($0.80) EPS, Q3 2017 earnings at ($0.85) EPS, Q4 2017 earnings at ($0.62) EPS, FY2017 earnings at ($3.06) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.89) EPS, Q3 2018 earnings at ($1.01) EPS, Q4 2018 earnings at ($0.85) EPS, FY2018 earnings at ($3.51) EPS, FY2019 earnings at ($3.49) EPS, FY2020 earnings at ($3.39) EPS and FY2021 earnings at ($3.08) EPS.

A number of other analysts have also commented on the company. Zacks Investment Research upgraded Corvus Pharmaceuticals from a hold rating to a buy rating and set a $14.00 price objective for the company in a research report on Monday, July 17th. Credit Suisse Group lowered their price objective on Corvus Pharmaceuticals from $26.00 to $17.00 and set an outperform rating for the company in a research report on Tuesday, July 4th. Finally, Cowen and Company reiterated an outperform rating on shares of Corvus Pharmaceuticals in a research report on Tuesday, July 4th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus target price of $20.50.

Shares of Corvus Pharmaceuticals (NASDAQ CRVS) traded up 0.60% during midday trading on Tuesday, reaching $11.68. 37,735 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $12.15 and a 200-day moving average of $12.83. The company’s market capitalization is $244.51 million. Corvus Pharmaceuticals has a 1-year low of $8.27 and a 1-year high of $22.14.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.03. Equities analysts expect that Corvus Pharmaceuticals will post ($3.18) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Rating Reaffirmed by Wedbush” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://theolympiareport.com/2017/08/12/corvus-pharmaceuticals-inc-nasdaqcrvs-stock-rating-reaffirmed-by-wedbush.html.

In related news, insider Richard A. Md Miller bought 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 13th. The stock was bought at an average cost of $9.88 per share, for a total transaction of $247,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Holdings A/S Novo bought 20,000 shares of the firm’s stock in a transaction dated Friday, June 23rd. The shares were bought at an average price of $10.95 per share, with a total value of $219,000.00. Following the completion of the transaction, the insider now directly owns 3,244,046 shares in the company, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.

Institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP bought a new position in Corvus Pharmaceuticals during the second quarter valued at about $320,000. Virtu KCG Holdings LLC bought a new position in Corvus Pharmaceuticals during the second quarter valued at about $213,000. Vanguard Group Inc. raised its position in Corvus Pharmaceuticals by 37.1% in the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after buying an additional 101,013 shares during the last quarter. Northern Trust Corp raised its position in Corvus Pharmaceuticals by 97.6% in the second quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock valued at $1,047,000 after buying an additional 42,739 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after buying an additional 9,099 shares during the last quarter. Institutional investors own 82.66% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.